Are timely access and robust safety mutually exclusive?
pharmaphorum
JULY 6, 2022
Of the 23 that received conditional marketing authorization in Europe, 10 (43%) went on to receive regular approval, and just one (4%) was withdrawn. The past decade has seen record numbers of new oncology therapy authorizations in the US and Europe. About the author.
Let's personalize your content